Toxicity Profile and Pharmacokinetic Study of A Phase I Low-Dose Schedule-Dependent Radiosensitizing Paclitaxel Chemoradiation Regimen for Inoperable Non-Small-Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 2, 2008, Pages 407-413

  Chen, Yuhchyau ^a   Pandya, Kishan J ^a   Feins, Richard ^b   Johnstone, David W ^c   Watson, Thomas ^a   Smudzin, Therese ^a   Keng, Peter C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chemoradiation; Non small cell lung cancer; Paclitaxel; Pharmacokinetics; Radiosensitization

Indexed keywords

DOSIMETRY; LIQUID CHROMATOGRAPHY; ONCOLOGY; PATIENT MONITORING; PHARMACOKINETICS; RADIOTHERAPY;

CHEMORADIATION; LUNG CANCER; RADIOSENSITIZATION;

CHEMOTHERAPY;

PACLITAXEL;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; ESOPHAGITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; NEUROPATHY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIATION-SENSITIZING AGENTS;

EID: 43049169911     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.10.011     Document Type: Article

References (26)

1. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692
3. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
4. Arriagada R., Le Chevalier T., Quoix E., et al. ASTRO Plenary: Effect of chemotherapy on locally advanced non-small-cell lung carcinoma: A randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20 (1991) 1183-1190
5. Sause W., Kolesar P., Taylor IV S., et al. Final results of phase III trial in regionally advanced unresectable non-small-cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
6. Morton R.F., Jett J.R., McGinnis W.L., et al. Thoracic radiation therapy alone compared with combined chemotherapy for locally unresectable non-small-cell lung cancer. Ann Intern Med 115 (1991) 681-686
7. Curran Jr. W.J., Scott C., Langer C., et al. Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer: Initial report of RTOG 9410. [Abstract]. Proc Am Soc Clin Oncol (2000)
8. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study. J Clin Oncol 14 (1996) 1065-1070
9. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small-cell lung cancer: A randomized study. Lung Cancer 46 (2004) 87-98
10. Clamon G., Herndon J., Cooper R., et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17 (1999) 4-11
11. Schiller J.H., Harrington D., Belani C.P., et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
12. Chen Y., Pandya K., Keng P., et al. Schedule dependent pulsed low-dose paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 24 (2001) 432-437
13. Chen Y., Pandya K., Keng P.C., et al. Phase I/II clinical trial using pulsed low-dose paclitaxel radiosensitization for thoracic malignancies: A therapeutic approach based on pre-clinical research of human lung cancer cells. Clin Cancer Res 9 (2003) 969-975
14. Common Toxicity Criteria, Version 2.0, National Institute of Health, National Cancer Institute, 1999, p. 25-26, 54-57.
15. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33 (1993) 48-52
16. Gianni L., Kearns C.M., Giani A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13 (1995) 180-190
17. Chen Y., and Okunieff P. Radiation and third generation chemotherapy. Hematol Oncol Clin North Am 18 (2004) 55-80
18. Vokes E.E., Herndon II J.E., Crawford J., et al. Randomized phased II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20 (2002) 4191-4198
19. Fletcher G.H. Clinical dose response curves of human malignant epithelial tumours. Br J Radiol 46 (1973) 151
20. Martel M.K., Ten Haken R.K., and Hazuka M.B. Estimation of tumor control probability parameters from 3-D dose distributions of non-small-cell lung cancer patients. Lung Cancer 24 (1999) 31-37
21. Mehta M., Scrimger R., Mackie R., et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49 (2001) 23-33
22. Dosoretz D.E., Galmari D., Rubenstein J.H., et al. Local control in medically inoperable lung cancer: An analysis of importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 27 (1993) 507-516
23. Krol A.D., Aussems P., Noordijk E.M., et al. Local irradiation alone for stage I lung cancer: Could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys 34 (1996) 297-302
24. Sibley G.S., Jamieson T.A., Marks L.B., et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys 40 (1998) 149-154
25. Reckzeh B., Merte H., Pfluger K.H., et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 14 (1996) 1071-1076
26. Movsas B., Scott C., Langer C., et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group (RTOG) 98-01. J Clin Oncol 23 (2005) 2145-2154